NorthRock Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

NorthRock Partners’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-5,420	Closed	-$294K	–	660
2025 Q3	$294K	Buy	5,420 +574	+12%	+$32.8K	0.01%	709
2025 Q2	$266K	Buy	+4,846	New	+$285K	0.01%	567

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NorthRock Partners's BMRN Position: Q4 2025 in Review

NorthRock Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 5,420 shares — an estimated $294K sold.

NorthRock Partners first reported a position in BMRN in Q2 2025 and held it in 2 quarters. The position peaked at $294K in Q3 2025. 539 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

NorthRock Partners reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
NorthRock Partners sold 5,420 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $294K.
NorthRock Partners first reported a position in BioMarin Pharmaceuticals in Q2 2025 and held it in 2 quarters.
NorthRock Partners's BioMarin Pharmaceuticals position peaked at $294K in Q3 2025.
539 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on NorthRock Partners's 13F filing for Q4 2025, filed 17 Feb 2026.